Literature DB >> 29447943

Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.

Noeman Ardalan1, Sako Mirzaie2, Abbas Akhavan Sepahi3, Ramazan Ali Khavari-Nejad4.   

Abstract

L-Asparaginases (ASNase) belong to a family of amidohydrolases, have both asparaginase and glutaminase activity. Acute lymphocytic leukemia (ALL) is an outrageous disease worldwide. Bacterial ASNase has been used for the treatment of ALL. Glutaminase activity of enzyme causes some side effect and it is not essential for anticancer activity. The aim of this study was engineering of Escherichia coli asparaginase II to find a mutant with reduced glutaminase activity by molecular docking, molecular dynamics (MD) and QM-MM (Quantum mechanics molecular dynamics) simulations. Residues with low free energy of binding to Asn and high free binding energy to Gln were chosen for mutagenesis. Then, a mutant with higher glutaminase free binding energy was selected for further studies. Additionally, the MD simulation and QM-MM computation of wild type (WT) were employed and the selected mutated ASNase were analyzed and discussed. Our data showed that V27T is a good candidate to reduction the glutaminase activity, while has no remarkable effect on asparaginase activity of the enzyme. The simulation analysis revealed that V27T mutant is more stable than WT and mutant simulation was successful completely. QM-MM results confirmed the successfulness of our mutagenesis.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute lymphocytic leukemia; Escherichia coli; Glutaminase activity; L-asparaginase; Molecular dynamics; QMMM studies

Mesh:

Substances:

Year:  2018        PMID: 29447943     DOI: 10.1016/j.mehy.2018.01.004

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  7 in total

Review 1.  Microbial L-asparaginase as a promising enzyme for treatment of various cancers.

Authors:  Farshad Darvishi; Zohreh Jahanafrooz; Ahad Mokhtarzadeh
Journal:  Appl Microbiol Biotechnol       Date:  2022-07-25       Impact factor: 5.560

Review 2.  Mechanisms of Proteolytic Enzymes and Their Inhibition in QM/MM Studies.

Authors:  Brigitta Elsässer; Peter Goettig
Journal:  Int J Mol Sci       Date:  2021-03-22       Impact factor: 5.923

3.  The Identification of Novel Inhibitors of Human Angiotensin-converting Enzyme 2 and Main Protease of Sars-Cov-2: A Combination of in silico Methods for Treatment of COVID-19.

Authors:  Vahid Zarezade; Hamzeh Rezaei; Ghodratollah Shakerinezhad; Arman Safavi; Zahra Nazeri; Ali Veisi; Omid Azadbakht; Mahdi Hatami; Mohamad Sabaghan; Zeinab Shajirat
Journal:  J Mol Struct       Date:  2021-04-06       Impact factor: 3.196

4.  Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).

Authors:  Noeman Ardalan; Abbas Akhavan Sepahi; Ramazan Ali Khavari-Nejad
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

5.  The SARS-Cov-2 Proliferation Blocked by a Novel and Potent Main Protease Inhibitor via Computer-aided Drug Design.

Authors:  Sepideh Shayan; Shahab Jamaran; Rafee Habib Askandar; Arian Rahimi; Azam Elahi; Chiako Farshadfar; Noeman Ardalan
Journal:  Iran J Pharm Res       Date:  2021       Impact factor: 1.696

Review 6.  Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles.

Authors:  Larissa Pereira Brumano; Francisco Vitor Santos da Silva; Tales Alexandre Costa-Silva; Alexsandra Conceição Apolinário; João Henrique Picado Madalena Santos; Eduardo Krebs Kleingesinds; Gisele Monteiro; Carlota de Oliveira Rangel-Yagui; Brahim Benyahia; Adalberto Pessoa Junior
Journal:  Front Bioeng Biotechnol       Date:  2019-01-10

Review 7.  Molecular Analysis of L-Asparaginases for Clarification of the Mechanism of Action and Optimization of Pharmacological Functions.

Authors:  Marina V Pokrovskaya; Vadim S Pokrovsky; Svetlana S Aleksandrova; Nikolay N Sokolov; Dmitry D Zhdanov
Journal:  Pharmaceutics       Date:  2022-03-09       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.